On March 17, 2026 Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics using its proprietary PrimeBody platform, reported a research collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The collaboration will evaluate Voro’s PrimeBody platform to generate masked antibody drug conjugate (ADC) candidates designed to improve therapeutic index through tumor-selective activation by incorporating proprietary masking domains and protease-cleavable linkers to keep biologics inactive in circulation and healthy tissues, with activation occurring selectively within the tumor microenvironment.
"Unlocking the full potential of highly potent payloads requires a new level of control over where and when activation occurs," said Ugur Eskiocak, Ph.D., Co-Founder and CEO of Voro Therapeutics. "PrimeBody is designed to potentially provide that level of control through tumor-selective activation and expand the target universe to include antigens historically considered too broadly expressed. We believe this approach has the potential to fundamentally expand the therapeutic index of ADCs. We are excited to collaborate with Daiichi Sankyo, a global leader in ADC innovation with a proven track record of developing transformative medicines for patients."
Under the agreement, Voro Therapeutics will apply its PrimeBody masking and linker technologies to design and characterize masked ADC candidates directed against a selected oncology target. The collaboration will leverage Voro’s previous experience and demonstrated success in creating tumor-activated biologics, including its lead CD47 blocker program, which has shown improved therapeutic index in preclinical studies.
(Press release, Voro Therapeutics, MAR 17, 2026, https://www.businesswire.com/news/home/20260317680457/en/Voro-Therapeutics-Announces-Research-Collaboration-with-Daiichi-Sankyo-to-Advance-PrimeBody-Technology-for-Next-Generation-Tumor-Activated-ADCs [SID1234663655])